"Leucovorin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
| Descriptor ID |
D002955
|
| MeSH Number(s) |
D03.633.100.733.631.400.800.350.450 D08.211.840.300.500
|
| Concept/Terms |
Leucovorin- Leucovorin
- Folinic Acid-SF
- Folinic Acid SF
- Leukovorin
- Leukovorum
- Folinic Acid
- Acid, Folinic
Citrovorum Factor- Citrovorum Factor
- Factor, Citrovorum
- Calcium Leucovorin
- Leucovorin, Calcium
- Calcium Folinate
- Folinate, Calcium
N(5)-Formyltetrahydrofolate- N(5)-Formyltetrahydrofolate
- 5-Formyltetrahydropteroylglutamate
- 5 Formyltetrahydropteroylglutamate
- 5-Formyltetrahydrofolate
- 5 Formyltetrahydrofolate
|
Below are MeSH descriptors whose meaning is more general than "Leucovorin".
Below are MeSH descriptors whose meaning is more specific than "Leucovorin".
This graph shows the total number of publications written about "Leucovorin" by people in this website by year, and whether "Leucovorin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1997 | 2 | 1 | 3 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2004 | 1 | 2 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leucovorin" by people in Profiles.
-
FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells. Int J Mol Sci. 2021 Jan 13; 22(2).
-
Aldh1l2 knockout mouse metabolomics links the loss of the mitochondrial folate enzyme to deregulation of a lipid metabolism observed in rare human disorder. Hum Genomics. 2020 11 09; 14(1):41.
-
Cytosolic 10-formyltetrahydrofolate dehydrogenase regulates glycine metabolism in mouse liver. Sci Rep. 2019 10 17; 9(1):14937.
-
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. Gastric Cancer. 2019 05; 22(3):577-586.
-
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
-
Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT. Bone Marrow Transplant. 2013 Jan; 48(1):46-9.
-
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):124-9.
-
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. Clin Colorectal Cancer. 2008 Mar; 7(2):134-9.
-
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007 Jun 01; 25(16):2205-11.
-
Leucovorin-induced resistance against FDH growth suppressor effects occurs through DHFR up-regulation. Biochem Pharmacol. 2006 Jul 14; 72(2):256-66.